A phase II, multicenter, single-arm trial of eribulin as first- or second-line chemotherapy for HER2-negative advanced or metastatic breast cancer: evaluation of efficacy, safety, and patient-reported outcomes

被引：0
|
作者：
Kosei Kimura
Mitsuhiko Iwamoto
Satoru Tanaka
Daigo Yamamoto
Katsuhide Yoshidome
Hiroyuki Ogura
Risa Terasawa
Nobuki Matsunami
Yuko Takahashi
Toshikatsu Nitta
Takashi Morimoto
Hiroya Fujioka
Kanako Kawaguchi
Kazuhisa Uchiyama
机构：
[1] Osaka Medical College Hospital,Department of Breast and Endocrine Surgery
[2] National Hospital Organization Osaka Minami Medical Center,Department of Breast Surgery
[3] Kansai Medical University Medical Center,Department of Breast Surgery
[4] Osaka Police Hospital,Department of Breast and Endocrine Surgery
[5] Hamamatsu University School of Medicine,Department of Breast Surgery
[6] Osaka Rosai Hospital,Department of Breast Surgery
[7] Hirakata City Hospital,Department of Breast and Endocrine Surgery
[8] Medico Shunju Shiroyama Hospital Breast Center,Division of Surgery
[9] Yao Municipal Hospital,Department of Breast Surgery
来源：
Cancer Chemotherapy and Pharmacology | 2018年 / 81卷
关键词：
Eribulin; Metastatic breast cancer; First or second-line; Objective response rate; QOL;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：923 / 933
页数：10
相关论文
共 50 条
  • [41] Sorafenib Plus Ixabepilone as First-Line Treatment of Metastatic HER2-Negative Breast Cancer: A Sarah Cannon Research Institute Phase I/II Trial
    Yardley, Denise A.
    Dickson, Natalie
    Drosick, David
    Earwood, Chris
    Inhorn, Roger
    Murphy, Patrick
    Hainsworth, John D.
    CLINICAL BREAST CANCER, 2016, 16 (03) : 180 - 187
  • [42] Phase II study of lapatinib in combination with vinorelbine, as first or second-line therapy in women with HER2 overexpressing metastatic breast cancer
    Chew, Helen Kent
    Schwartzberg, Lee
    Badarinath, Suprith
    Rubin, Peter
    Shumaker, Grace
    Daugherty, James
    DeSilvio, Michelle
    Mahoney, Janine
    SPRINGERPLUS, 2014, 3
  • [43] Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life
    Palumbo, Raffaella
    Sottotetti, Federico
    Trifiro, Giuseppe
    Piazza, Elena
    Ferzi, Antonella
    Gambaro, Anna
    Spinapolice, Elena Giulia
    Pozzi, Emma
    Tagliaferri, Barbara
    Teragni, Cristina
    Bernardo, Antonio
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 : 2189 - 2199
  • [44] Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer
    D W Miles
    S L de Haas
    L Y Dirix
    G Romieu
    A Chan
    X Pivot
    P Tomczak
    L Provencher
    J Cortés
    P R Delmar
    S J Scherer
    British Journal of Cancer, 2013, 108 : 1052 - 1060
  • [45] Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer
    J. Salvador
    L. Manso
    J. de la Haba
    A. Jaen
    E. Ciruelos
    M. C. de Villena
    M. Gil
    A. Murias
    A. Galan
    C. Jara
    J. Bayo
    J. M. Baena
    J. Casal
    J. R. Mel
    I. Blancas
    P. Sanchez Rvira
    Clinical and Translational Oncology, 2015, 17 : 160 - 166
  • [46] Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer
    Miles, D. W.
    de Haas, S. L.
    Dirix, L. Y.
    Romieu, G.
    Chan, A.
    Pivot, X.
    Tomczak, P.
    Provencher, L.
    Cortes, J.
    Delmar, P. R.
    Scherer, S. J.
    BRITISH JOURNAL OF CANCER, 2013, 108 (05) : 1052 - 1060
  • [47] Phase II Interventional Study (N0337) of Capecitabine in Combination With Vinorelbine and Trastuzumab for First- or Second-Line Treatment of HER2-Positive Metastatic Breast Cancer: A North Central Cancer Treatment Group Trial
    Tan, Winston W.
    Allred, Jacob B.
    Salim, Muhammad
    Flynn, Patrick
    Fishkin, Paul A. S.
    Stella, Philip J.
    Wiesenfeld, Martin
    Bernath, Albert M.
    Fitch, Tom R.
    Perez, Edith A.
    CLINICAL BREAST CANCER, 2012, 12 (02) : 81 - 86
  • [48] A prognostic factor index for overall survival in patients receiving first-line chemotherapy for HER2-negative advanced breast cancer: An analysis of the ATHENA trial
    Llombart-Cussac, Antonio
    Pivot, Xavier
    Biganzoli, Laura
    Cortes-Funes, Hernan
    Pritchard, Kathleen I.
    Pierga, Jean-Yves
    Smith, Ian
    Thomssen, Christoph
    Srock, Stefanie
    Sampayo, Miguel
    Cortes, Javier
    BREAST, 2014, 23 (05) : 656 - 662
  • [49] Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer
    Salvador, J.
    Manso, L.
    de la Haba, J.
    Jaen, A.
    Ciruelos, E.
    de Villena, M. C.
    Gil, M.
    Murias, A.
    Galan, A.
    Jara, C.
    Bayo, J.
    Baena, J. M.
    Casal, J.
    Mel, J. R.
    Blancas, I.
    Sanchez Rvira, P.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2015, 17 (02) : 160 - 166
  • [50] Phase II trial of biweekly administration with eribulin after three cycles of induction therapy in hormone receptor-positive, HER2-negative metastatic breast cancer (JACCRO BC-03)
    Kobayashi, Kokoro
    Masuda, Norikazu
    Mizuno, Toshiro
    Miura, Kayo
    Tokuda, Yutaka
    Yoshinami, Tetsuhiro
    Kawaguchi, Hidetoshi
    Ohtani, Shoichiro
    Saeki, Toshiaki
    Toi, Masakazu
    Takeuchi, Masahiro
    Ito, Yoshinori
    BREAST CANCER RESEARCH AND TREATMENT, 2023, 201 (03) : 409 - 415
12345